2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
June 2, 2017
Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
BURNABY, British Columbia, June 02, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Jefferies 2017 Healthcar... More >>
May 9, 2017
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company today, reported its financial results for the quarter ended March 31, 2017, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon's Pres... More >>
May 4, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 04, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 first quarter financial and operating results after the close of U.S. financial markets on Tuesday, May 9, ... More >>
April 28, 2017
Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 28, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. ... More >>
April 26, 2017
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-out in Q1 2018 and Phase 2 proof-of-concept clinical trial beginning in mid-2018 Conference call to be held today at 9:00 am ET BURNABY, British Columbia, April 26, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), ... More >>
March 24, 2017
Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne
Company to Hold Conference Call at 8:30 am ET Today BURNABY, British Columbia, March 24, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, ... More >>
March 8, 2017
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, March 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2016, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon's Pr... More >>
March 1, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 01, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2017. Xe... More >>
January 8, 2017
Xenon Pharmaceuticals Outlines Key Milestones for 2017
BURNABY, British Columbia, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2017. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “As we en... More >>